

Bimekizumab[Barbeque-man](#)

Bimekizumab is an inhibitor of interleukin 17A and 17F, and refers to immunoglobulin monoclonal antibody used to treat moderate and severe plaque psoriasis.

Ustekinumab[US-Tech-man](#)

Psoriasis patients are found to respond to treatment that interferes with lymphocyte activation, the tumor necrosis factor (TNF) pathway, agents blocking interleukin (IL)-17, or the IL-12/23p40 subunit. Ustekinumab is a fully human immunoglobulin G1? (IgG1?) monoclonal antibody that targets the p40 subunit shared by IL-12 and IL-23.

Ixekizumab[Exit-man with I-shaker](#)

Ixekizumab is an IL-17A antagonist used to treat moderate to severe plaque psoriasis. It should be avoided in patients with inflammatory bowel disease.

Secukinumab[Second \(2nd\)-man](#)

Secukinumab is an IL-17A antagonist used to treat moderate to severe plaque psoriasis.
